+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07542704

Evaluating Safety, Tolerability, and Efficacy of Oral KQB368 in Adults With Advanced Solid Tumors Having KRAS G12C or G12S Mutations

Led by Kumquat Biosciences Inc. · Updated on 2026-11-03

48

Participants Needed

14

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating KQB368 as a possible treatment for adults with advanced solid tumors, including colorectal cancer, non-small cell lung cancer, uterine cancer, and tumors with KRAS G12C or G12S mutations. This Phase 11b study aims to determine the safe dose of KQB368 when used alone, assess its effect on tumor size, and understand how the drug behaves in the body. Participants will take KQB368 orally every day in 21-day cycles. The study starts with dose escalation to find the right dose and then expands to further evaluate safety and effectiveness. During the first 5 weeks, participants will visit the study site about 7 times, followed by visits at the start of each 21-day cycle thereafter. Throughout the study, participants will undergo assessments to measure tumor response, survival, drug levels in the blood, and other health indicators. These include scans to measure tumor size according to RECIST criteria and evaluations of how long the response lasts. The study will monitor participants for up to 44 months to collect data on safety, tolerability, and how well KQB368 controls the disease.

CONDITIONS

Brief Title

A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

Research Team

K

Kumquat Clinical Development Telephone

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here